PD 1 Monotherapy Lengthens PFS in dMMR Endometrial Cancer

Company Merck Event Type Phase 3 results and publication Modality Anti-PD-1 antibody Asset Pembrolizumab (KEYNOTE-C93) Target PD-1 Disease Area Mismatch-repair-deficient advanced or recurrent endometrial cancer Summary Global Phase III KEYNOTE-C93 data presented and published online 26 October show markedly longer progression-free survival with pembrolizumab alone…